Abstract
Background: In 2020, the pandemic caused by novel coronavirus infection has become one of the most critical global health challenges during the past century. The lack of a vaccine, as the most effective way to control the novel infection, has prompted the development of a large number of preventive products by the scientific community. We have developed a candidate vaccine (EpiVacCorona) against novel coronavirus infection caused by SARS-CoV-2 that is based on chemically synthesized peptides conjugated to a carrier protein and adsorbed on aluminum hydroxide and studied the specific activity of the developed vaccine.
 Aims: Study of the immunogenicity and protectivity of the peptide candidate vaccine EpiVacCorona.
 Materials and methods: the work was performed using standard molecular biological, virological and histological methods.
 Results: It was demonstrated that EpiVacCorona, when administered twice, spaced 14 days apart, to hamsters, ferrets, and non-human primates (African green monkeys, rhesus macaques) at a dose of 260 g, which is equal to one inoculation dose for humans, induces virus-specific antibodies in 100% of the animals. Experiments in hamsters showed this vaccine to be associated with the dose-dependent immunogenicity. The vaccine was shown to accelerate the elimination of the virus from the upper respiratory tract in ferrets and prevent the development of pneumonia in hamsters and non-human primates following a respiratory challenge with novel coronavirus.
 Conclusions: The results of a preclinical specific activity study indicate that the use of EpiVacCorona has the potential for human vaccination.
Highlights
In 2020, the pandemic caused by novel coronavirus infection has become one of the most critical global health challenges during the past century
We have developed a candidate vaccine (EpiVacCorona) against novel coronavirus infection caused by SARSCoV-2 that is based on chemically synthesized peptides conjugated to a carrier protein and adsorbed on aluminum hydroxide and studied the specific activity of the developed vaccine
It was demonstrated that EpiVacCorona, when administered twice, spaced 14 days apart, to hamsters, ferrets, and non-human primates at a dose of 260 μg, which is equal to one inoculation dose for humans, induces virus-specific antibodies in 100% of the animals
Summary
Нами была разработана кандидатная вакцина (ЭпиВакКорона) против новой коронавирусной инфекции SARS-CoV-2 на основе химически синтезированных пептидов, конъюгированных на белок-носитель и адсорбированных на гидроксид алюминия, и изучена ее специфическая активность. Для цитирования: Рыжиков А.Б., Рыжиков Е.А., Богрянцева М.П., Даниленко Е.Д., Иматдинов И.Р., Нечаева Е.А., Пьянков О.В., Пьянкова О.Г., Суслопаров И.М., Таранов О.С., Гудымо А.С., Данильченко Н.В., Слепцова Е.С., Боднев С.А., Онхонова Г.С., Петров В.Н., Моисеева А.А., Торжкова П.Ю., Пьянков С.А., Трегубчак Т.В., Антонец Д.В., Гаврилова Е.В., Максютов Р.А. Ные пептиды были конъюгированы с белком-носителем, Цель исследования — изучение специфических иммув качестве которого был выбран N-белок нового корона- ногенных и протективных свойств кандидатной пептидвируса, поскольку он консервативен и содержит вирус- ной вакцины против SARS-CoV-2. В работе были использованы лабораторные животвведения, содержащую композицию химически синтези- ные, чувствительные к коронавирусной инфекции, тарованных пептидных иммуногенов S-белка коронавиру- кие как низшие приматы, сирийские хомяки и хорьса SARS-CoV-2, конъюгированных с белком-носителем ки.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
